1
|
Hatch ND, Ouellette SP. Identification of the alternative sigma factor regulons of Chlamydia trachomatis using multiplexed CRISPR interference. mSphere 2023; 8:e0039123. [PMID: 37747235 PMCID: PMC10597470 DOI: 10.1128/msphere.00391-23] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2023] [Accepted: 08/07/2023] [Indexed: 09/26/2023] Open
Abstract
Chlamydia trachomatis is a developmentally regulated, obligate intracellular bacterium that encodes three sigma factors: σ66, σ54, and σ28. σ66 is the major sigma factor controlling most transcription initiation during early- and mid-cycle development as the infectious elementary body (EB) transitions to the non-infectious reticulate body (RB) that replicates within an inclusion inside the cell. The roles of the minor sigma factors, σ54 and σ28, have not been well characterized to date; however, there are data to suggest each functions in late-stage development and secondary differentiation as RBs transition to EBs. As the process of secondary differentiation itself is poorly characterized, clarifying the function of these alternative sigma factors by identifying the genes regulated by them will further our understanding of chlamydial differentiation. We hypothesize that σ54 and σ28 have non-redundant and essential functions for initiating late gene transcription thus mediating secondary differentiation in Chlamydia. Here, we demonstrate the necessity of each minor sigma factor in successfully completing the developmental cycle. We have implemented and validated multiplexed Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) interference techniques, novel to the chlamydial field to examine the effects of knocking down each alternative sigma factor individually and simultaneously. In parallel, we also overexpressed each sigma factor. Altering transcript levels for either or both alternative sigma factors resulted in a severe defect in EB production as compared to controls. Furthermore, RNA sequencing identified differentially expressed genes during alternative sigma factor dysregulation, indicating the putative regulons of each. These data demonstrate that the levels of alternative sigma factors must be carefully regulated to facilitate chlamydial growth and differentiation. IMPORTANCE Chlamydia trachomatis is a significant human pathogen in both developed and developing nations. Due to the organism's unique developmental cycle and intracellular niche, basic research has been slow and arduous. However, recent advances in chlamydial genetics have allowed the field to make significant progress in experimentally interrogating the basic physiology of Chlamydia. Broadly speaking, the driving factors of chlamydial development are poorly understood, particularly regarding how the later stages of development are regulated. Here, we employ a novel genetic tool for use in Chlamydia while investigating the effects of dysregulating the two alternative sigma factors in the organism that help control transcription initiation. We provide further evidence for both sigma factors' essential roles in late-stage development and their potential regulons, laying the foundation for deeper experimentation to uncover the molecular pathways involved in chlamydial differentiation.
Collapse
Affiliation(s)
- Nathan D. Hatch
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Scot P. Ouellette
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, USA
| |
Collapse
|
2
|
Ramirez YA, Adler TB, Altmann E, Klemm T, Tiesmeyer C, Sauer F, Kathman SG, Statsyuk AV, Sotriffer C, Kisker C. Structural Basis of Substrate Recognition and Covalent Inhibition of Cdu1 from Chlamydia trachomatis. ChemMedChem 2018; 13:2014-2023. [PMID: 30028574 PMCID: PMC6177307 DOI: 10.1002/cmdc.201800364] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2018] [Revised: 07/17/2018] [Indexed: 01/12/2023]
Abstract
Based on the similarity between the active sites of the deubiquitylating and deneddylating enzyme ChlaDub1 (Cdu1) and the evolutionarily related protease adenain, a target-hopping screening approach on a focused set of adenain inhibitors was investigated. The cyanopyrimidine-based inhibitors identified represent the first active-site-directed small-molecule inhibitors of Cdu1. High-resolution crystal structures of Cdu1 in complex with two covalently bound cyanopyrimidines, as well as with its substrate ubiquitin, were obtained. These structural data were complemented by enzymatic assays and covalent docking studies to provide insight into the substrate recognition of Cdu1, active-site pocket flexibility and potential hotspots for ligand interaction. Combined, these data provide a strong basis for future structure-guided medicinal chemistry optimization of this cyanopyrimidine scaffold into more potent and selective Cdu1 inhibitors.
Collapse
Affiliation(s)
- Yesid A. Ramirez
- Prof. Dr. C. Kisker, Y.A. Ramirez, T. Klemm, C. Tiesmeyer, Dr. F. Sauer, Rudolf Virchow Center for Experimental Biomedicine, Institute of Structural Biology, University of Würzburg, Josef-Schneider-Straße 2, 97080 Würzburg, Germany.,
- Prof. Dr. C. Sotriffer, Dr. T. B. Adler, Institute of Pharmacy and Food Chemistry, University of Würzburg, Am Hubland C7, 97074 Würzburg, Germany.,
| | - Thomas B. Adler
- Prof. Dr. C. Sotriffer, Dr. T. B. Adler, Institute of Pharmacy and Food Chemistry, University of Würzburg, Am Hubland C7, 97074 Würzburg, Germany.,
| | - Eva Altmann
- Dr. E. Altmann, Novartis Institute for Biomedical Research, Novartis Campus, 4002 Basel, Switzerland
| | - Theresa Klemm
- Prof. Dr. C. Kisker, Y.A. Ramirez, T. Klemm, C. Tiesmeyer, Dr. F. Sauer, Rudolf Virchow Center for Experimental Biomedicine, Institute of Structural Biology, University of Würzburg, Josef-Schneider-Straße 2, 97080 Würzburg, Germany.,
| | - Christian Tiesmeyer
- Prof. Dr. C. Kisker, Y.A. Ramirez, T. Klemm, C. Tiesmeyer, Dr. F. Sauer, Rudolf Virchow Center for Experimental Biomedicine, Institute of Structural Biology, University of Würzburg, Josef-Schneider-Straße 2, 97080 Würzburg, Germany.,
| | - Florian Sauer
- Prof. Dr. C. Kisker, Y.A. Ramirez, T. Klemm, C. Tiesmeyer, Dr. F. Sauer, Rudolf Virchow Center for Experimental Biomedicine, Institute of Structural Biology, University of Würzburg, Josef-Schneider-Straße 2, 97080 Würzburg, Germany.,
| | - Stefan G. Kathman
- S. G. Kathman, Northwestern University, Department of Chemistry., Silverman Hall, Sheridan Road 2145, Evanston, 60208 Illinois, USA
| | - Alexander V. Statsyuk
- Dr. A. V. Statsyuk, University of Houston College of Pharmacy, Calhoun Road 7037, 4849 Houston, USA
| | - Christoph Sotriffer
- Prof. Dr. C. Sotriffer, Dr. T. B. Adler, Institute of Pharmacy and Food Chemistry, University of Würzburg, Am Hubland C7, 97074 Würzburg, Germany.,
| | - Caroline Kisker
- Prof. Dr. C. Kisker, Y.A. Ramirez, T. Klemm, C. Tiesmeyer, Dr. F. Sauer, Rudolf Virchow Center for Experimental Biomedicine, Institute of Structural Biology, University of Würzburg, Josef-Schneider-Straße 2, 97080 Würzburg, Germany.,
| |
Collapse
|